Gubra A/S (CPH:GUBRA)

Market Cap	4.97B -27.2%
Revenue (ttm)	271.02M -89.7%
Net Income	-182.25M
EPS	-11.16
Shares Out	16.42M
PE Ratio	n/a
Forward PE	65.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,116
Open	305.80
Previous Close	304.60
Day's Range	302.20 - 308.20
52-Week Range	290.20 - 557.50
Beta	0.31
Analysts	Buy
Price Target	501.00 (+65.57%)
Earnings Date	Mar 3, 2027

About Gubra

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinfor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 330
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: GUBRA

Analyst Summary

According to 3 analysts, the average rating for GUBRA stock is "Buy." The 12-month stock price target is kr 501.00, which is an increase of 65.57% from the latest price.

Price Target

kr 501.00

(65.57% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error